These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 598046)

  • 21. Response to tamoxifen and fluoxymesterone in a group of breast cancer patients with disease recurrence after cessation of adjuvant tamoxifen.
    Fornander T; Rutqvist LE; Glas U
    Cancer Treat Rep; 1987; 71(7-8):685-8. PubMed ID: 3300966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An evaluation of five drug combination chemotherapy in the management of recurrent carcinoma of the breast.
    Lee JM; Abeloff MD; Lenhard RE; Baker RR
    Surg Gynecol Obstet; 1974 Jan; 138(1):77-80. PubMed ID: 4809006
    [No Abstract]   [Full Text] [Related]  

  • 23. [Mechanism and classification of hormone therapy for human breast cancer studied by changes of SHBG binding capacity].
    Murayama Y
    Gan No Rinsho; 1984 Dec; 30(15):1879-82. PubMed ID: 6543230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical management of metastatic breast cancer.
    Lawrence W; Brown PW; Terz JJ
    Surgery; 1977 Aug; 82(2):173-81. PubMed ID: 69328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Rise in serum creatinine under the androgen fluoxymesterone in chronic renal disease (author's transl)].
    Schulz E; Heinecke G
    MMW Munch Med Wochenschr; 1976 Nov; 118(48):1559-62. PubMed ID: 826797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Vincristine, adriamycin, mitomycin-C and UFT (VAM-UFT) therapy in progressive or recurrent breast cancer].
    Yasutake K; Imamura Y; Yoshimura Y; Oya M; Matsushita K; Hozumi T; Katou J; Okutani T; Irie K
    Gan To Kagaku Ryoho; 1989 Jul; 16(7):2373-9. PubMed ID: 2502072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.
    Nishimura R; Okumura Y; Arima N
    Breast Cancer; 2008; 15(1):57-64. PubMed ID: 18224396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Supplemental hormone treatment of operable breast neoplasms].
    Ehlers PN
    Langenbecks Arch Chir; 1970 Dec; 327(1):407-13. PubMed ID: 5526076
    [No Abstract]   [Full Text] [Related]  

  • 29. [Use of a combination of pyrogenal and drug preparations in the overall treatment of breast cancer].
    Kovalenko AV
    Klin Khir (1962); 1980 May; (5):50-1. PubMed ID: 6771456
    [No Abstract]   [Full Text] [Related]  

  • 30. [Tamoxifen in treating disseminated breast cancer].
    Dement'eva NP; Ass NIa; Koroleva LA; Lipovich MM; Stsetsevich NV
    Vopr Onkol; 1981; 27(8):30-4. PubMed ID: 7281591
    [No Abstract]   [Full Text] [Related]  

  • 31. Evaluation of estrogen dependency of human breast cancers. II. Clinical evaluation of tamoxifen in advanced primary and recurrent breast cancer.
    Nishiki M; Yamane M; Amano K; Yasuda K; Okumichi T; Ezaki H
    Hiroshima J Med Sci; 1984 Jun; 33(2):163-6. PubMed ID: 6480380
    [No Abstract]   [Full Text] [Related]  

  • 32. [Hormone treatment of breast cancer in the advanced phase].
    Demol R
    Brux Med; 1968 Oct; 48(10):665-9. PubMed ID: 5757971
    [No Abstract]   [Full Text] [Related]  

  • 33. Cytotoxic drug and hormone therapy after adrenalectomy for advanced breast cancer.
    Keating JL; Yonemoto RH; Byron RL
    Surg Gynecol Obstet; 1968 Sep; 127(3):538-42. PubMed ID: 4969618
    [No Abstract]   [Full Text] [Related]  

  • 34. Continuous postoperative treatment with cyclophosphamide in breast carcinoma--a randomized clinical study.
    Rieche K; Berndt H; Prahl B
    Arch Geschwulstforsch; 1972; 40(4):349-54. PubMed ID: 4650821
    [No Abstract]   [Full Text] [Related]  

  • 35. Fluoride therapy for pain in malignant bone disease.
    Scott WP
    Radiology; 1968 Mar; 90(3):588-90. PubMed ID: 4966742
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of anemia associated with multiple myeloma.
    Bergsagel DE; Fitzgerald B; Quirt I; Meharchand J; Hasselback R
    N Engl J Med; 1991 Jan; 324(1):59-60. PubMed ID: 1984168
    [No Abstract]   [Full Text] [Related]  

  • 37. Results of four years of intermittent human growth hormone (hGH) and fluoxymesterone therapy in hypopituitary dwarfism.
    Kirkland RT; Harrist RB; Clayton GW
    Pediatrics; 1980 Mar; 65(3):562-6. PubMed ID: 7360545
    [No Abstract]   [Full Text] [Related]  

  • 38. The thermoprofile as an early indicator of breast cancer response to hormonal therapy.
    Stoll BA
    Cancer; 1971 Jun; 27(6):1379-83. PubMed ID: 4325984
    [No Abstract]   [Full Text] [Related]  

  • 39. Combination chemotherapy for disseminated carcinoma of the breast.
    Lozada JA; Grillo-López A; Vélez-Garciá E
    Bol Asoc Med P R; 1975 Jun; 67(6):157-63. PubMed ID: 1055588
    [No Abstract]   [Full Text] [Related]  

  • 40. [Survival and factors related to the survival of recurrent breast cancer patients--a study with quantification theory].
    Murayama Y
    Gan No Rinsho; 1983 Apr; 29(4):A-20, 311-4. PubMed ID: 6687908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.